GENE ONLINE|News &
Perspectives
[Illustrations] 2026 TechBio Stress Test: Can AI Deliver Real Drugs as Recursion, Insilico Medicine and Schrödinger Take Center Stage
2026-02-06
[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
2026-02-05
[Illustrations] 2026 Obesity’s Second Wave: Market Fragmentation Starts to Challenge First-Generation Dominance
2026-02-05
[Illustrations] 2026 Biopharma’s “Clearing Year”: IRA, BIOSECURE, and the Phase 3 Threshold Becoming the True Litmus Test
2026-02-05
Moderna and Recordati Form Strategic Alliance to Commercialize mRNA Therapy for Propionic Acidemia
2026-02-04
From CRISPR to National Security: How Rare Diseases Became America’s Next Strategic Industry
2026-02-03
Sanofi’s Venglustat Demonstrates Superiority Over ERT in Phase 3 Type 3 Gaucher Disease Trial
2026-02-02
[Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector
2026-01-30
[Illustrations] The Global and Taiwan Orphan Drug Market Heads Into 2026 With New Rules, New Prices, and New Pressure Points
2026-01-29
LATEST
Trip.com Group Limited to Release Q4 and Full-Year 2025 Financial Results on February 25, 2026
2026-02-09
FireFox Gold Reports 54.91 g/t Gold Over 1.95 Meters in Northeast Zone Expansion at Mustajärvi Project
2026-02-09
